Return to Trial Database

HCRN-BRE18-334

A Phase II circulating tumor DNA enriched, genomically directed post-neoadjuvant trial for patients with residual triple negative breast cancer (PERSEVERE)

Status

Enrollment Closed

Cancer Type(s)

Study Contact

studies@hoosiercancer.org

Trial Locations

All sites in which the trial HCRN-BRE18-334 being conducted in.

Advocate Aurora Research Institute (Illinois)

Aurora Health Care

Froedtert & the Medical College of Wisconsin

Georgetown Lombardi Comprehensive Cancer Center

Indiana University Melvin and Bren Simon Comprehensive Cancer Center

Miami Cancer Institute at Baptist Health, Inc.

Novant Health Oncology Specialists

The University of Chicago Medicine Comprehensive Cancer Center

University of Alabama at Birmingham Comprehensive Cancer Center

University of Wisconsin Carbone Cancer Center

UT Health San Antonio MD Anderson Cancer Center